ThrombUS Horizon EU Project

Deep vein thrombosis (DVT) poses a significant health risk, with potentially life-threatening consequences when left undetected. ThrombUS is set to redefine DVT care with an ambitious mission to develop an innovative wearable diagnostic device for point-of-care, operator-free, continuous monitoring. DVT involves the formation of blood clots in deep veins, primarily in the lower limbs, leading to blood flow obstruction. Shockingly, up to two-thirds of DVT cases exhibit no clinical symptoms, making early diagnosis challenging. ThrombUS steps in to bridge this gap, bringing together a diverse team of experts spanning industry, technology, regulation, social science, and clinical trials. Our interdisciplinary approach centers around creating a novel wearable diagnostic device utilizing autonomous, AI-driven DVT detection. This groundbreaking device incorporates wearable ultrasound hardware, impedance plethysmography, and light reflection rheography for immediate clot detection. Activity and physiological measurements will continuously assess DVT risk, supporting prevention through serious gaming. An intelligent decision support unit will provide real-time monitoring and alerts, with extended reality guiding users for optimal device utilization. With a duration of 42 months, ThrombUS kicks off on January 1, 2024, and concludes on June 30, 2027. The project has 18 partners from Greece, Lithuania, France, Germany, the USA, Italy, Finland, and Spain. The Horizon Europe Innovation Action funds the venture with 9.5 M€. ThrombUS will leverage big datasets collected through three large-scale clinical studies for AI training. Validation will be carried out in clinical settings through one early feasibility study and one multi-center clinical trial. Learn more at thrombus.eu #thrombosis #DVT #earlydetection #HorizonEurope

📣 We are officially accepting applications for Associated Partners! Associated Partners will be invited to have detailed knowledge of project deliverables and collaborate on certain research and innovation areas with ThrombUS partners to the benefit of the project, producing collaborative research and innovation. Associated Partners will be chosen based on: -     overall quality of partner profile; -     relevance of partner activities to ThrombUS ; -     emphasis on Medical Partners that may wish to uptake research results and participate in clinical studies and clinical trials; -     emphasis on SMEs and large industry that may wish to uptake or contribute towards research and innovation results If you believe your organization would be a good fit for the consortium, download the application at https://lnkd.in/dYKFxaqp. We would love to work with you! #HorizonEurope #DeepVeinThrombosis

Today was an exciting and important day for me. I've started studying electrical engineering to deepen my knowledge of biomedical engineering and to become active in the field of medicine. Many steps later, today was the first time I was able to give a presentation to doctors. I presented the ThrombUS Horizon EU Project project, and the audience was particularly interested in AI and cutting-edge microelectronics. Afterwards, I realized how important it is to work together on an interdisciplinary basis. I am sure that more microelectronics can be used in medicine. I feel that the interest and mutual enthusiasm is growing. Many thanks to the DGA 2024(Deutschen Gesellschaft für Angiologie – Gesellschaft für Gefäßmedizin e.V.)and the Fraunhofer IPMS IPMS for giving me this opportunity.

Last week the ThrombUS project was presented by Marco Kircher of Fraunhofer Institute for Photonic Microsystems IPMS at Deutsche Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin e.V. (DGA), hosted by the German Society of Angiology. This marks an exciting moment as it is the second time the ThrombUS project has been presented at a scientific conference this year. View the presentation (German): https://lnkd.in/d4pMy3pZ Conference site: https://lnkd.in/dyudvWxE #thrombosis #wearable #deepveinthrombosis #dvt #AI #ultrasound

Fraunhofer Institute for Photonic Microsystems IPMS based in Dresden, Germany, is this month's featured project partner. For ThrombUS , Fraunhofer IPMS is developing ultrasound transducer arrays for the portable component, which will enable continuous monitoring of DVT (Deep Vein Thrombosis) directly on site. We are focusing on our CMUTs (Capacitive Micromachined Ultrasonic Transducers), which are MEMS-based transducers considered the next generation of medical ultrasound devices. Their advantages open up the possibility of developing a completely new diagnostic system. Read more about Fraunhofer IPMS, their history, and their involvement in the project at: https://lnkd.in/djWxX-5h #DVT #Ultrasound #HorizonEurope #transducer #EarlyDetection

🚑 Revolutionizing Deep Vein Thrombosis Detection with AI-Powered Wearables! 🦵🤖 The VDE, through ThrombUS Horizon EU Project , is breaking new ground in the early detection and prevention of deep vein thrombosis (DVT) with #AI-based wearables. This innovative device integrates sensors for ultrasound, electrical impedance, and light reflection, offering continuous and highly sensitive monitoring. ⚙️💡 With real-time #AI analysis, healthcare professionals can easily access the data on various devices, improving post-operative care and home monitoring. #AI #MedTech #Wearables #HealthcareInnovation #DVT

In Germany alone, 40,000 to 100,000 deaths are caused by pulmonary embolisms every year. Up to 60% of venous thromboembolisms occur during hospitalisation or within 90 days afterwards. Venous thromboses occur in both the superficial and deep veins of the legs and pelvis. Around 50,000 people in Germany suffer from superficial vein thrombosis every year, and the prevalence increases with age. Up to 25% of those affected develop #DeepVeinThrombosis, which is associated with a higher risk of pulmonary embolism. We can prevent pulmonary embolism and save lives by acting quickly when venous thrombosis is suspected. While early diagnosis is challenging, ThrombUS steps in to bridge this gap, bringing together a diverse team of experts spanning industry, technology, regulation, social science, and clinical trials. Our interdisciplinary approach centers around creating a novel wearable diagnostic device utilizing autonomous, AI-driven #DVT detection. This groundbreaking device incorporates wearable #ultrasound hardware, impedance plethysmography, and light reflection rheography for immediate clot detection. Activity and physiological measurements will continuously assess DVT risk, supporting prevention through serious gaming. An intelligent decision support unit will provide real-time monitoring and alerts, with extended reality guiding users for optimal device utilization. Sources: WorldThrombosisDay (https://lnkd.in/dw4-XENY) (https://lnkd.in/d7p6ibVM) Deutsche Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin e.V. (DGA) (https://lnkd.in/ds7259r8) Viatris (https://lnkd.in/dnqvEsWU) Number of the Month provided by ThrombUS partner medis Medizinische Messtechnik GmbH #HorizonEurope #Thrombosis #AI #EarlyDetection

Deep vein thrombosis (DVT) poses a significant health risk, with potentially life-threatening consequences when left undetected. ThrombUS is set to redefine DVT care with an ambitious mission to develop an innovative wearable diagnostic device for point-of-care, operator-free, continuous monitoring. DVT involves the formation of blood clots in deep veins, primarily in the lower limbs, leading to blood flow obstruction. Shockingly, up to two-thirds of DVT cases exhibit no clinical symptoms, making early diagnosis challenging. ThrombUS steps in to bridge this gap, bringing together a diverse team of experts spanning industry, technology, regulation, social science, and clinical trials. Our interdisciplinary approach centers around creating a novel wearable diagnostic device utilizing autonomous, AI-driven DVT detection. This groundbreaking device incorporates wearable ultrasound hardware, impedance plethysmography, and light reflection rheography for immediate clot detection. Activity and physiological measurements will continuously assess DVT risk, supporting prevention through serious gaming. An intelligent decision support unit will provide real-time monitoring and alerts, with extended reality guiding users for optimal device utilization. With a duration of 42 months, ThrombUS kicks off on January 1, 2024, and concludes on June 30, 2027. The project has 18 partners from Greece, Lithuania, France, Germany, the USA, Italy, Finland, and Spain. The Horizon Europe Innovation Action funds the venture with 9.5 M€. ThrombUS will leverage big datasets collected through three large-scale clinical studies for AI training. Validation will be carried out in clinical settings through one early feasibility study and one multi-center clinical trial. Learn more at thrombus.eu #thrombosis #DVT #earlydetection #HorizonEurope

In Germany alone, 40,000 to 100,000 deaths are caused by pulmonary embolisms every year. Up to 60% of venous thromboembolisms occur during hospitalisation or within 90 days afterwards. Venous thromboses occur in both the superficial and deep veins of the legs and pelvis. Around 50,000 people in Germany suffer from superficial vein thrombosis every year, and the prevalence increases with age. Up to 25% of those affected develop #DeepVeinThrombosis, which is associated with a higher risk of pulmonary embolism. We can prevent pulmonary embolism and save lives by acting quickly when venous thrombosis is suspected. While early diagnosis is challenging, ThrombUS steps in to bridge this gap, bringing together a diverse team of experts spanning industry, technology, regulation, social science, and clinical trials. Our interdisciplinary approach centers around creating a novel wearable diagnostic device utilizing autonomous, AI-driven #DVT detection. This groundbreaking device incorporates wearable #ultrasound hardware, impedance plethysmography, and light reflection rheography for immediate clot detection. Activity and physiological measurements will continuously assess DVT risk, supporting prevention through serious gaming. An intelligent decision support unit will provide real-time monitoring and alerts, with extended reality guiding users for optimal device utilization. Sources: WorldThrombosisDay (https://lnkd.in/dw4-XENY) (https://lnkd.in/d7p6ibVM) Deutsche Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin e.V. (DGA) (https://lnkd.in/ds7259r8) Viatris (https://lnkd.in/dnqvEsWU) Number of the Month provided by ThrombUS partner medis Medizinische Messtechnik GmbH #HorizonEurope #Thrombosis #AI #EarlyDetection